Reaction

Colonoscopy reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,175 reports · 48 co-occurring drugs

As of the last recalculation, Colonoscopy appears in 2,175 FAERS reports alongside 48 co-occurring drug terms. The strongest observed disproportionality signal is TOLVAPTAN (PRR 16.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tolvaptan	25	16.6	16.7
Avapritinib	17	13.5	13.6
Niraparib	26	11.3	11.3
Epoprostenol	14	10.3	10.3
Oral Semaglutide	73	9.8	9.8
Tolterodine Tartrate	8	8.6	8.6
Riociguat	27	8.0	8.0
Relugolix	19	7.8	7.8
Sodium Oxybate	50	7.4	7.4
Bosentan	38	7.3	7.3
Velpatasvir And Sofosbuvir	9	6.7	6.7
Calcium, Magnesium, Potassium, And Sodium Oxybates	6	6.7	6.7
Umeclidinium	6	6.4	6.4
Armodafinil	14	6.4	6.4
Fluticasone Furoate	8	6.3	6.3
Macitentan	45	6.3	6.3
Pancrelipase	25	6.3	6.3
Icosapent Ethyl	5	5.6	5.6
Ibrutinib	46	5.5	5.5
Ambrisentan	65	5.1	5.1
Patiromer	7	4.9	4.9
Selexipag	13	4.8	4.8
Fluticasone Furoate And Vilanterol Trifenatate	18	4.8	4.8
Ranolazine	5	4.6	4.6
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	4.6	4.6
Dofetilide	5	4.6	4.6
Teduglutide	6	4.3	4.3
Umeclidinium Bromide And Vilanterol Trifenatate	7	4.0	4.0
Fexofenadine Hydrochloride	9	4.0	4.0
Belimumab	12	3.6	3.6
Bimekizumab	8	3.6	3.6
Teriparatide	41	3.5	3.5
Cenobamate	3	3.4	3.4
Voxelotor	8	3.4	3.4
Treprostinil	41	3.2	3.2
Certolizumab Pegol	38	3.1	3.1
Abiraterone	4	2.8	2.8
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	12	2.8	2.8
Orlistat	7	2.6	2.6
Conjugated Estrogens And Medroxyprogesterone Acetate	6	2.4	2.4
Ixekizumab	9	2.3	2.3
Elexacaftor, Tezacaftor, And Ivacaftor	3	2.3	2.3
Evolocumab	36	2.1	2.1
Pimavanserin Tartrate	12	2.1	2.1
Alirocumab	5	1.9	1.9
Apremilast	28	1.8	1.8
Abaloparatide	5	1.6	1.6
Erenumab-Aooe	9	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.